^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Checkmate 040 Cohort 5: long-term efficacy and safety of nivolumab in patients with ChildPugh B advanced hepatocellular carcinoma and associations between baseline biomarker analyses and outcomes
Published date:
06/26/2021
Excerpt:
Patients with CPB 7 or 8 aHCC (sorafenib naive n = 25; sorafenib treated n = 24) received nivolumab 240 mg intravenously for 30 minutes every 2 weeks...Lower tumor expression of PD-1 and CD163 was associated with longer OS (Fig)...
Trial ID:
